<article id="cooper_2011" class="slide" data-ag-slide-name="Cooper 2011">
    <div class="basic">
      <h1 data-ag-editable="Cooper 2011 Main Title">With Neulasta<sup>®</sup> primary prophylaxis you can offer your patients better protection from FN than with daily G-CSF (filgrastim)<sup>1</sup></h1>
      <div id="ne_page1_graph1_holder" class="main_content_style">
         <img src="content/images/carer_pages/neulasta_efficacy/ne_page1_graph2.png" width="375" height="290" data-ag-editable="Cooper 2011 Graph 1 Background" />
          <div id="cooper_2011_graph1_content">
              <h2 id="graph1_title" data-ag-editable="Cooper 2011 Graph 1 Title">Relative risk of FN compared to no primary G-CSF prophylaxis</h2>
              <p id="graph1_legend1" data-ag-editable="Cooper 2011 Graph 1 Legend 1">filgrastim</p>
              <p id="graph1_legend2"  data-ag-editable="Cooper 2011 Graph 1 Legend 2">Neulasta<sup>®</sup></p>
              <p id="graph1_vertical_axis_title"  data-ag-editable="Cooper 2011 Graph 1 Vertical Axis Title">Relative risk (95%CI)</p>
              <ul id="graph1_vertical_axis_value" data-ag-editable="Cooper 2011 Graph 1 Vertical Axis Values">
                  <li>0.6</li>
                  <li>0.5</li>
                  <li>0.4</li>
                  <li>0.3</li>
                  <li>0.2</li>
                  <li>0.1</li>
                  <li>0</li>
              </ul>
              <p id="graph1_bottom_text">Adapted from Cooper KL <span class="et_al">et al.</span> BMC Cancer 2011;23(11);404</p>

          </div>
         <div id="ne_page1_graph1_arrow1">
            <img src="content/images/carer_pages/neulasta_efficacy/ne_page1_graph_data1.png" width="100" height="209" data-ag-editable="Cooper 2011 Graph 1 Left Bar" />
             <p id="cooper_2011_graph1_bar1_text" data-ag-editable="Cooper 2011 Graph 1 Bar 1 Value"><span>0.57*</span><br/><br/>P&lt;,00001<br/>[95% CI: 0.48-0.69]</p>
         </div>
         <div id="ne_page1_graph1_arrow2">
            <img src="content/images/carer_pages/neulasta_efficacy/ne_page1_graph_data2.png" width="99" height="96" data-ag-editable="Cooper 2011 Graph 1 Right Bar" />
             <p id="cooper_2011_graph1_bar2_text" data-ag-editable="Cooper 2011 Graph 1 Bar 2 Value">53%</p>
         </div>
         <div id="ne_page1_graph1_arrow3">
            <img src="content/images/carer_pages/neulasta_efficacy/ne_page1_graph_data3.png" width="100" height="105" data-ag-editable="Cooper 2011 Graph 1 Right Arrow" />
             <p id="cooper_2011_graph1_bar3_text" data-ag-editable="Cooper 2011 Graph 1 Bar 3 Value"><span>0.3</span><sup>†</sup><br/><br/>P&lt;,0.002<br/>[95% CI: 0.14-0.65]</p>
         </div>
      </div>
      <div id="ne_page1_graph2_holder" class="main_content_style">
         <img src="content/images/carer_pages/neulasta_efficacy/ne_page1_graph2.png" width="382" height="296" data-ag-editable="Cooper 2011 Graph 2 Background" />
          <div id="cooper_2011_graph2_content">
              <h2 id="graph2_title" data-ag-editable="Cooper 2011 Graph 2 Title">Relative risk of FN: Primary prophylaxis with Neulasta<sup>®</sup> compared<br/> to Filgrastim</h2>
              <p id="graph2_legend1" data-ag-editable="Cooper 2011 Graph 2 Legend 1">filgrastim</p>
              <p id="graph2_legend2"  data-ag-editable="Cooper 2011 Graph 2 Legend 2">Neulasta<sup>®</sup></p>
              <p id="graph2_vertical_axis_title"  data-ag-editable="Cooper 2011 Graph 2 Vertical Axis Title">Relative risk (95%CI)</p>
              <ul id="graph2_vertical_axis_value" data-ag-editable="Cooper 2011 Graph 2 Vertical Axis Values">
                  <li>0.6</li>
                  <li>0.5</li>
                  <li>0.4</li>
                  <li>0.3</li>
                  <li>0.2</li>
                  <li>0.1</li>
                  <li>0</li>
              </ul>
              <p id="graph2_bottom_text" data-ag-editable="Cooper 2011 Graph 2 Bottom Text">Adapted from Cooper KL <span class="et_al">et al.</span> BMC Cancer 2011;23(11);404</p>

          </div>
         <div id="ne_page1_graph2_arrow1">
            <img src="content/images/carer_pages/neulasta_efficacy/ne_page1_graph2_data1.png" width="101" height="177" data-ag-editable="Cooper 2011 Graph 2 Left Bar" />
             <p id="cooper_2011_graph2_bar1_text" data-ag-editable="Cooper 2011 Graph 2 Bar 1 Value"><span>1.00</span></p>
         </div>
         <div id="ne_page1_graph2_arrow2">
            <img src="content/images/carer_pages/neulasta_efficacy/ne_page1_graph2_data2.png" width="96" height="64" data-ag-editable="Cooper 2011 Graph 2 Right Bar" />
             <p id="cooper_2011_graph2_bar2_text" data-ag-editable="Cooper 2011 Graph 2 Bar 2 Value">33%</p>
         </div>
         <div id="ne_page1_graph2_arrow3">
            <img src="content/images/carer_pages/neulasta_efficacy/ne_page1_graph2_data3.png" width="101" height="111" data-ag-editable="Cooper 2011 Graph 2 Right Arrow" />
             <p id="cooper_2011_graph2_bar3_text" data-ag-editable="Cooper 2011 Graph 2 Bar 3 Value"><span>0.66</span><sup>†</sup><br/><br/>P=0.04<br/>[95% CI: 0.44-0.98]</p>
         </div>
      </div>
      <div id="ne_page1_image1" class="image_style"></div>
      <div id="ne_page1_data_bottom" class="main_content_style">
         <!--<p data-ag-editable="Cooper 2011 Bottom Left Copy">The risk of FN is significantly lower for patients given Neulasta<sup>®</sup> primary prophylaxis compared to daily filgrastim<sup> ‡1</sup></p>
         <div id="ne_page1_data_bottom_cta_btn"></div>-->
         <div id="ne_page1_data_bottom_cta_copy"><p data-ag-editable="Cooper 2011 Bottom Right Copy">The risk of FN is <strong>one third less likely</strong> for patients given Neulasta<sup>®</sup> primary prophylaxis compared to daily filgrastim<sup>‡1</sup></p></div>
      </div>
    </div>
    <!-- Reference Information Starts -->
    <div class="lightbox_data" id="cooper_2011_refs">
       <div class="main_content_style">
          <p><strong data-ag-editable="Cooper 2011 References Title">References:</strong></p>
          <div data-ag-editable="Cooper 2011 References List">
             <ol>
                <li>Cooper KL <em>et al</em>. Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis. BMC Cancer 2011; 23(11):404</li>
             </ol>
          </div>
          <p data-ag-editable="Cooper 2011 References Bottom Copy">* A meta-analysis of 2183 patients in ten randomized, controlled trials<br />
          † A meta-analysis of 2060 patients in five randomized, controlled trials<br />
          ‡ A meta-analysis of 606 patients in five randomized, controlled trials. Pegfilgrastim vs Filgrastim relative risk of FN (95% CI) 0.66 (0.44 to 0.98) p=0.04</p>
       </div>
    </div>
    <!-- Reference Information Ends -->
</article>